Skip to main content
DBV Technologies logo

DBV Technologies — Investor Relations & Filings

Ticker · DBV ISIN · FR0010417345 LEI · 969500PVBQFWQKVDMD80 PA Manufacturing
Open in API
Filings indexed 1,036 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country FR France
Listing PA DBV

About DBV Technologies

https://www.dbv-technologies.com/

DBV Technologies is a clinical-stage biopharmaceutical company developing treatments for food allergies and other immunological diseases. The company's core technology is Viaskin®, a proprietary investigational platform based on epicutaneous immunotherapy (EPIT). This non-invasive patch technology is designed to re-educate the immune system by delivering minimal amounts of antigens through intact skin. DBV's lead product candidate, Viaskin Peanut (DBV712), is in late-stage clinical development for the treatment of peanut allergies in pediatric patients. The development pipeline also includes Viaskin Milk (DBV135) for milk allergies, with the platform holding potential for applications beyond food allergies.

Recent filings

Filing Released Lang Actions
DBV Technologies publie ses résultats financiers du 1er trimestre 2026
Regulatory Filings
2026-04-30 French
DBV Technologies Reports First Quarter 2026 Financial Results
Regulatory Filings
2026-04-30 English
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a brief regulatory disclosure of the company’s total number of shares and voting rights as of a specific date, referencing Article 223-16 of the AMF rules. This is a voting rights announcement rather than an AGM presentation, full report, or capital transaction. It matches the “Declaration of Voting Results & Voting Rights Announcements” category.
2026-04-02 English
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 mars 2026
Regulatory Filings Classification · 1% confidence The document is a very short regulatory disclosure under Article 223-16 of the AMF General Regulation, providing the total number of shares and voting rights as of March 31, 2026. It is not a full financial report, earnings release, management announcement, dividend notice, or threshold crossing. It simply fulfills a mandatory regulatory announcement requirement. Therefore, it falls under the fallback category “Regulatory Filings” (RNS).
2026-04-02 French
Franchissement de seuils
Major Shareholding Notification Classification · 1% confidence The document is an AMF filing under article L.233-7 of the French Commercial Code declaring the crossing of shareholding thresholds by J.P. Morgan Chase & Co. It details percentages of capital and voting rights held after the threshold breach. This is a Major Shareholding Notification.
2026-04-02 French
Franchissement de seuils
Major Shareholding Notification Classification · 1% confidence The document is a formal AMF declaration titled “Déclaration de franchissement de seuils” under article L.233-7 of the French Commercial Code. It reports that MPM BioImpact LLC has crossed the 5% ownership threshold in DBV Technologies, detailing the new share count and percentage. This matches the Major Shareholding Notification category (notification of crossing shareholding thresholds).
2026-04-02 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.